

Cardiac Comorbidities in Early Stage Prostate Cancer in Active Surveillance

Jeong Oh (The UT MD Anderson Cancer Center, USA), John Davis (The UT MD Anderson Cancer Center, USA), Karen Hoffman (The UT MD Anderson Cancer Center, USA), Sijin Wen (The UT MD Anderson Cancer Center, USA), Sarah Taylor (The UT MD Anderson Cancer Center, USA), Angela Abouassi (The UT MD Anderson Cancer Center, USA), Rena Day (School of Public Health at The UT Health Science Center at Houston, USA), Jeri Kim (The UT MD Anderson Cancer Center, USA).

BACKGROUND: Active surveillance is a viable option for patients with early stage prostate cancer. Studies have suggested that cardiac comorbidities may play significant role in the prognosis of these patients.

OBJECTIVES: To describe the prevalence of cardiac comorbidities and severity in patients of clinically localized prostate cancer undergoing Active Surveillance.

METHODS: 228 patients with clinically localized prostate cancer (clinical stage (T1/T2), prostate-specific antigen level (<10 ng/mL), Gleason score 7 or less), enrolled in a prospective cohort study of Active Surveillance between 2/1/2006-12/31/2008. Cardiac comorbidities/ severity index and overall comorbidity severity scores were obtained using Adult Comorbidity Evaluation 27 index.

RESULTS: Overall comorbidity based on ACE-27 index showed that 51 patients (22.4%) had moderate or severe comorbidities. Most common group of comorbidities were Cardiac (65.8%), Endocrine (13.6%), Other Malignancies (9.6%), Respiratory (5.6%), and Neurological (3.9%). Cardiac severity score was moderate or severe in 14% of the patients. Table 1 lists the most common cardiac comorbidities and their severity.

CONCLUSIONS: Prevalence of cardiac comorbidities was high in patients undergoing Active Surveillance and may play a significant role in the morbidity and mortality of patients with localized disease. Further studies are ongoing we plan to determine the role of these comorbidities and their severity in long term morbidity and mortality.

Table 1: Cardiovascular Comorbidities				
	Mild	Moderate	Severe	Total
Hypertension	114 (52.2%)	19 (8.3%)	0 (0%)	133 (60.5%)
Angina Pectoris	51 (21.5%)	3 (1.3%)	0 (0%)	54 (22.8%)
Myocardial Infarction	2 (0.9%)	9 (3.9%)	0 (0%)	11 (4.8%)
Congestive Heart Failure	2 (0.9%)	0 (0%)	0 (0%)	2 (0.9%)
Peripheral Arterial Disease	2 (0.9%)	0 (0%)	0 (0%)	2 (0.9%)
Thromboembolism	0 (0%)	1 (0.4%)	1 (0.4%)	2 (0.9%)
Cardiac Arrhythmias	0 (0%)	1 (0.4%)	0 (0%)	1 (0.4%)